Squamous cell carcinoma in a patient receiving sorafenib;Survenue d'un carcinome spinocellulaire chez un patient traité par sorafenib

Annales de Dermatologie et de Venereologie

Volumn 138, Issue 2, 2011, Pages 120-123

  Adnot Desanlis, L ^a   Bernard, P ^a   Reguiai Z ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Adverse event; Sorafenib; Squamous cell carcinoma; Vascular endothelial growth factor; VEGF

Indexed keywords

SORAFENIB;

ADULT; ARTICLE; CASE REPORT; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; MALE; MEDICAL HISTORY; RETROAURICULAR SQUAMOUS CELL CARCINOMA; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TISSUE DIFFERENTIATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BIOPSY; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; COOPERATIVE BEHAVIOR; FOLLOW-UP STUDIES; HUMANS; INTERDISCIPLINARY COMMUNICATION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; PYRIDINES; SKIN; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951949841     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2010.04.026     Document Type: Article

References (15)

1. Autier J, Mateus C, Weschler J, Spatz A, Escudier B, Robert C. Effets secondaires cutanés du sorafenib et du sunitinib. Ann Dermatol Venereol 2008;135:148-53. (Pubitemid 351625321)
2. Deslandres M, Sibaud V, Chevreau C, Delord JP. Effets secondaires cutanés des nouvelles molécules anticancéreuses : focus sur les molécules ciblant les récepteurs tyrosine kinase et le récepteur à l'EGF. Ann Dermatol Venereol 2008;135:S16-24.
3. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-51.
4. Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J. Keratoacanthome multiples éruptifs induits par le sorafenib. Ann Dermatol Venereol 2009;136:894-7.
5. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-2.
6. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009;35:1766-70.
7. Dubauskas Z, Kunishige J, Prieto VG, Jonasch, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-3.
8. Arnault JP, Wechsler J, Escudier B, Spatz A, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:59-61.
9. Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol 2009;61:522-7.
10. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008;144:779-82. (Pubitemid 351846880)
11. Cribier B. Vous avez dit kératoacanthome ? Dites plutôt «carcinome spinocellulaire à type de kératoacanthome». Ann Dermatol Venereol 2008;135:541-6.
12. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006;31:783-5. (Pubitemid 44563396)
13. Mirones I, Conti CJ, Martinez, Garcia M, Larcher F. Complexity of VEGF responses in skin carcinogenesis revealed through ex vivo assays based on a VEGF-A null mouse keratinocyte cell line. J Invest Dermatol 2009;129:730-41.
14. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657-67.
15. Hipp MM, Hilf N, Walter S, Werth D, Radsak MP, Weinschenk T, et al. Sorafenib but not sunitinib, affects function of dendritic cells and induction of primary immune response. Blood 2008;111:5610-20.